£135 million for two life sciences funds, rare disease R&D, Beacon Therapeutics, Basecamp Research’s Series C, Birmingham Life Sciences Week, Liberal Democrat party conference, Women in Biotech Edinburgh
The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.
In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.
There are a number of significant moving pieces right now in the sector, including the major strategic shift at UKRI and Innovate launched last Thursday.
Outpost Bio has raised $3.5 million in pre-seed funding to build frontier AI models that make human microbiology computable, enabling more precise prediction and optimization of intervention outcomes.
Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme.
A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.
In this guest blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.
Bidwells has completed the merger of Creative Places LLP into the firm, strengthening its Science & Technology capability and further enhancing its expertise in R&D and innovation-led real estate.
Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.
Working closely with BIA’s FTAC and HMRC, FTI Consulting have devoted a great deal of time interpreting the new legislation for qualifying overseas expenditure and guidance.
The first in a new series of skills webinars for the BIA Finance and Tax Community explored some of the most significant milestones in a company’s growth journey, with insights and reflections from experts with firsthand experience.
BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.
The 2025 Budget arrived at a pivotal moment for the UK’s life sciences and biotech sector, amid global instability, funding pressures, and potential policy shifts that could reshape the industry. Watch BIA's latest webinar recording as they unpack the key announcements, their impact, and how they align with the government’s Life Sciences Sector Plan and wider industrial strategy.
